Metagenomi, Inc. Common Stock (MGX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Metagenomi, Inc. Common Stock (MGX) has a cash flow conversion efficiency ratio of -0.173x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-19.51 Million) by net assets ($112.57 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see MGX stock market capitalisation for the company's overall valuation and market capitalisation.
Metagenomi, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how Metagenomi, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Metagenomi, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Metagenomi, Inc. Common Stock ranked by their cash flow conversion efficiency. See Metagenomi, Inc. Common Stock (MGX) debt coverage ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Mudajaya Group Bhd
KLSE:5085
|
-0.012x |
|
Cyclopharm Ltd
AU:CYC
|
-0.362x |
|
Reading International Inc
NASDAQ:RDI
|
0.097x |
|
Econpile Holdings Bhd
KLSE:5253
|
0.006x |
|
HS Valve Co. Ltd
KQ:039610
|
0.001x |
|
Theralase Technologies Inc.
V:TLT
|
-0.180x |
|
Rompetrol Well
RO:PTR
|
0.020x |
|
SKILLCAST GROUP LS -001
F:K9I
|
N/A |
Annual Cash Flow Conversion Efficiency for Metagenomi, Inc. Common Stock (2021–2025)
The table below shows the annual cash flow conversion efficiency of Metagenomi, Inc. Common Stock from 2021 to 2025. View Metagenomi, Inc. Common Stock (MGX) stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | $158.60 Million | $-88.89 Million | -0.560x | -20.69% |
| 2024-09-30 | $234.86 Million | $-109.07 Million | -0.464x | -168.89% |
| 2023-09-30 | $-135.58 Million | $-91.41 Million | 0.674x | +268.81% |
| 2022-09-30 | $-74.43 Million | $29.72 Million | -0.399x | +46.42% |
| 2021-09-30 | $-32.54 Million | $24.26 Million | -0.745x | -- |
About Metagenomi, Inc. Common Stock
Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company's lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia. It has a collaboration agreement with Ionis Pharmaceuticals, Inc. for apolipoprotein C-III for … Read more